homepage-02 By Posted August 16, 2014 In homepage-022014-08-162014-08-16https://apyxmedical.com/wp-content/uploads/2018/12/apyx-logo-footer_orange-white_150w.pngApyx Medicalhttps://apyxmedical.com/wp-content/uploads/2018/12/apyx-logo-footer_orange-white_150w.png200px200px 0 Recent PostsAPYX MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS; INTRODUCES FULL YEAR 2023 FINANCIAL OUTLOOKAPYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION TO COAGULATE AND CONTRACT SOFT TISSUES, INCLUDING SUBCUTANEOUS TISSUE, WHERE NEEDEDAPYX MEDICAL CORPORATION ANNOUNCES NEW FIVE-YEAR CREDIT AGREEMENT WITH MIDCAP FINANCIALAPYX MEDICAL CORPORATION TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIAL RESULTS ON MARCH 16, 2023
